Karyopharm (KPTI) Reports Q2 2025 Earnings with Mixed Financial Results
Karyopharm (KPTI) reported Q2 2025 earnings with a 6% increase in XPOVIO net product revenue to $29.7 million, but total revenue declined to $37.9 million from $42.8 million in the same period in 2024. The company saw a reduction in R&D and SG&A expenses, but higher interest expenses and a net loss of $37.3 million impacted its financial performance.
Tickers: $KPTI
Topics: earnings report expenses financial results net loss revenue